CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC

CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC

Alexandria TM Lee,1 Misako Nagasaka1,2 1University of California Irvine School of Medicine, Department of Medicine, Orange, CA, 92868, USA; 2St. Marianna University School of Medicine, Department of Medicine, Kawasaki, JapanCorrespondence: Misako Nagasaka, Department of Medicine, University of Calif...

Full description

Bibliographic Details
Main Authors: Lee ATM, Nagasaka M
Format: Article
Language:English
Published: Dove Medical Press 2023-04-01
Series:Lung Cancer: Targets and Therapy
Subjects:
immunotherapy
epidermal growth factor receptor mutation
osimertinib refractory
Online Access:https://www.dovepress.com/checkmate-722-the-rise-and-fall-of-nivolumab-with-chemotherapy-in-tki--peer-reviewed-fulltext-article-LCTT

Internet

https://www.dovepress.com/checkmate-722-the-rise-and-fall-of-nivolumab-with-chemotherapy-in-tki--peer-reviewed-fulltext-article-LCTT

Similar Items